GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-04. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
==== Apixaban binding to factor Xa ==== Apixaban shows a similar binding mode as rivaroxaban and forms a tight inhibitor-enzyme complex when connected to FXa. The p-methoxy group of apixaban connects to S1 pocket of FXa but does not appear to have any interaction with any residues in this region of FXa. The pyrazole N-2 nitrogen atom of apixaban interacts with Gln-192 and the carbonyl oxygen interacts with Gly-216. The phenyl lactam group of apixaban is positioned between Tyr-99 and Phe-174 and due to its orientation, it is able to interact with Trp-215 of the S4 pocket. The carbonyl oxygen group of the lactam moiety interacts with a water molecule and does not seem to interact with any residues in the S4 pocket.
In biomolecules, proteins can be separated by ion exchange chromatography. Biological proteins are made up of zwitterionic amino acid compounds; the net charge of these proteins can be positive or negative depending on the pH of the environment. The specific pI of the target protein can be used to model the process around and the compound can then be purified from the rest of the mixture. Buffers of various pH can be used for this purification process to change the pH of the environment. When a mixture containing a target protein is loaded into an ion exchanger, the stationary matrix can be either positively-charged (for mobile anions) or negatively-charged (for mobile cations). At low pH values, the net charge of most proteins in the mixture is positive – in cation exchangers, these positively-charged proteins bind to the negatively-charged matrix. At high pH values, the net charge of most proteins is negative, where they bind to the positively-charged matrix in anion exchangers. When the environment is at a pH value equal to the protein's pI, the net charge is zero, and the protein is not bound to any exchanger, and therefore, can be eluted out.
octet rule Also Lewis octet rule. A classical rule for describing the electron configuration of atoms in certain molecules: the maximum number of electron pairs that can be accommodated in the valence shell of an element in the first row of the periodic table is four (or eight total electrons). For elements in the second and subsequent rows, there are many exceptions to this rule.
This Michaelis–Menten equation is the basis for most single-substrate enzyme kinetics. Two crucial assumptions underlie this equation (apart from the general assumption about the mechanism only involving no intermediate or product inhibition, and there is no allostericity or cooperativity). The first assumption is the so-called quasi-steady-state assumption (or pseudo-steady-state hypothesis), namely that the concentration of the substrate-bound enzyme (and hence also the unbound enzyme) changes much more slowly than those of the product and substrate and thus the change over time of the complex can be set to zero.
Sources: en.wikipedia.org
=== Adolescent mental health === Adolescence is a period when many mental health conditions first appear. Teenagers face major physical, social, and emotional changes that can increase stress and create challenges for their well-being. Research shows that early mental health support helps prevent long-term problems and improves development.
=== Sex pheromone === The sex pheromone of the American cockroach is the sequiterpene (1Z,5E)-1,10(14)-diepoxy-4(15),5-germacradien-9-one, which has been given the trivial name periplanone-B. This pheromone was isolated from the feces of virgin female cockroaches. Previously, 2,2-dimethyl-3-isopropylidenecyclopropyl propionate had been thought to be the structure of this pheromone, but on synthesis was shown to be inactive. The structure determination of this pheromone was an eventful chapter in the history of pheromone chemistry.
=== Galactose metabolism === No direct catabolic pathways exist for galactose metabolism. Galactose is therefore preferentially converted into glucose-1-phosphate, which may be shunted into glycolysis or the inositol synthesis pathway. GALE functions as one of four enzymes in the Leloir pathway of galactose conversion of glucose-1-phosphate. First, galactose mutarotase converts β-D-galactose to α-D-galactose. Galactokinase then phosphorylates α-D-galactose at the 1' hydroxyl group, yielding galactose-1-phosphate. In the third step, galactose-1-phosphate uridyltransferase catalyzes the reversible transfer of a UMP moiety from UDP-glucose to galactose-1-phosphate, generating UDP-galactose and glucose-1-phosphate. In the final Leloir step, UDP-glucose is regenerated from UDP-galactose by GALE; UDP-glucose cycles back to the third step of the pathway. As such, GALE regenerates a substrate necessary for continued Leloir pathway cycling. The glucose-1-phosphate generated in step 3 of the Leloir pathway may be isomerized to glucose-6-phosphate by phosphoglucomutase. Glucose-6-phosphate readily enters glycolysis, leading to the production of ATP and pyruvate. Furthermore, glucose-6-phosphate may be converted to inositol-1-phosphate by inositol-3-phosphate synthase, generating a precursor needed for inositol biosynthesis.
SumoPred-PLM or SUMOylation site Prediction using Protein Language Model - An AI deep learning utility to predict based on known biological rules around SUMO2 and SUMO3 binding in human proteins incorporating knowledge from a separate pretrained PLM tool developed previously in 2021 by Elnaggar et al. known as ProtT5-XL-UniRef50. Such collaboration between multidisciplinary AI tools is becoming common practice.
WHO suggests assessing workers' exposure in workplaces with methods similar to those used for the proposed specific occupational exposure limit (OEL) value of the MNM (conditional recommendation, low-quality evidence). Because there are no specific regulatory OEL values for MNMs in workplaces, WHO suggests assessing whether workplace exposure exceeds a proposed OEL value for the MNM. A list of proposed OEL values is provided in an annex of the guidelines. The chosen OEL should be at least as protective as a legally mandated OEL for the bulk form of the material (conditional recommendation, low-quality evidence). If specific OELs for MNMs are not available in workplaces, WHO suggests a step-wise approach for inhalation exposure with, first an assessment of the potential for exposure; second, conducting basic exposure assessment and third, conducting a comprehensive exposure assessment such as those proposed by the Organisation for Economic Cooperation and Development (OECD) or Comité Européen de Normalisation (the European Committee for Standardization, CEN) (conditional recommendation, moderate quality evidence). For dermal exposure assessment, WHO found that there was insufficient evidence to recommend one method of dermal exposure assessment over another. C. Control exposure to MNMs
Sources: en.wikipedia.org
Foster (1895–1970), Manhattan Project chemist and the first female chemist to work for the United States Geological Survey Antoine François, comte de Fourcroy (1775–1809), co-discovered the element Iridium and developed modern chemical notation Joanna Fowler (born 1942), American neural chemist who studied effects on the human brain and radiotracers in brain chemistry Michelle Francl (PhD 1983), American computational chemist known for the 6-31G* basis set for Na to Ar and electrostatic potential charges Edward Frankland (1825–1899), English chemist, one of the originators of organometallic chemistry who introduced the concept of valence Rosalind Franklin (1920–1958), British chemist and crystallographer whose work was central to understanding the molecular structure of DNA Katherine Franz (born 1972), American chemist noted for work in metal ion coordination in biological systems Herman Frasch (1851–1914), German mining engineer and inventor, pioneered the Frasch process Bertram Fraser-Reid (1934–2020), Jamaican synthetic organic chemist who developed the armed-disarmed principle in glycosylation chemistry Helen Murray Free (1923–2021), American chemist who developed self-testing systems for diabetes Carl Remigius Fresenius (1818–1897), German chemist known for work in analytical chemistry Ida Freund (1863–1914), British chemist known for texts on chemistry teaching, andy first woman university chemistry lecturer in the UK Charles Friedel (1832–1899), French chemist, developer of Friedel–Crafts reaction Alexander Naumovich Frumkin (1895–1976), electrochemist and chemist who develped applied electrochemical processes related to chemical sources of electrical power Kenichi Fukui (1918–1998), 1981 Nobel Prize in Chemistry for investigating mechanisms of chemical reactions Elizabeth Fulhame (18th–19th centuries), British chemist, pioneer in the study of catalysis and discoverer of photoreduction Vera Furness (1921–2002), English chemist and industrial manager who worked on the production of the acrylic Courtelle
== Medical use == Mebeverine is used to alleviate some of the symptoms of irritable bowel syndrome (IBS) and related conditions; specifically stomach pain and cramps, persistent diarrhoea, and flatulence. Historically data from controlled clinical trials have not found a difference from placebo or statistically significant results in the global improvement of IBS. However, a 2022 systematic review found that Mebeverine is an effective treatment option in IBS, with a good safety profile and low frequency of adverse effects. It has not been tested in pregnant women nor in pregnant animals so pregnant women should not take it; it is expressed at low levels in breast milk, while no adverse effects have been reported in infants, breastfeeding women should not take this drug.
==== Pulmonary tissues ==== Lung tissue engineering focuses on developing functional respiratory structures to treat end-stage pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). Due to the complex, highly vascularized three-dimensional architecture of the lung, which comprises over forty distinct cell types and a delicate alveolar-capillary basement membrane, whole-organ biofabrication typically relies on decellularized donor lung scaffolds. This process strips away immunogenic cellular material while preserving the native extracellular matrix geometry and mechanical compliance required for ventilation. Research strategies prioritize the multi-lineage recellularization of these scaffolds using patient-specific induced pluripotent stem cells (iPSCs) differentiated into alveolar epithelial cells (type I and II) and microvascular endothelial cells. Additionally, biomimetic microfluidic platforms, or "lung-on-a-chip" models, are utilized to study cellular shear stress and gas-exchange dynamics, serving as precursors to transplantable bioartificial lung devices.
== External links == LPAR6 human gene location in the UCSC Genome Browser. LPAR6 human gene details in the UCSC Genome Browser. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
One way to effectively deal with the inherent multi-physics and the control systems development that is involved when including intelligent systems, is to adopt the V-Model approach to systems development, as has been widely used in the automotive industry for twenty years or more. In this V-approach, system-level requirements are propagated down the V via subsystems to component design, and the system performance is validated at increasing integration levels. Engineering of mechatronic systems requires the application of two interconnected "V-cycles": one focusing on the multi-physics system engineering (like the mechanical and electrical components of an electrically powered steering system, including sensors and actuators); and the other focuses on the controls engineering, the control logic, the software and realization of the control hardware and embedded software.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.